+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Correlation of VEGF and VEGFR2 expression with anti-tumor efficacy of VEGFR2 tyrosine kinase inhibitors and an anti-VEGF monoclonal antibody in xenografts



Correlation of VEGF and VEGFR2 expression with anti-tumor efficacy of VEGFR2 tyrosine kinase inhibitors and an anti-VEGF monoclonal antibody in xenografts



Proceedings of the American Association for Cancer Research Annual Meeting 44: 933




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 034654834

Download citation: RISBibTeXText


Related references

Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumour models. British Journal of Cancer 91(7): 1391-1398, 2004

Targeting Vascular Endothelial Growth Factor (VEGF) for Anti-tumor Therapy, by Anti-VEGF Neutralizing Monoclonal Antibodies or by VEGF Receptor Tyrosine-kinase Inhibitors. Cancer and Metastasis Reviews 18(4): 473-481, 1999

Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors. Cancer Metastasis Reviews 18(4): 473-481, 2000

Anti-VEGF antibody, 2C3, down-regulates expression of mouse VEGFR2 receptor Flk-1, inhibits tumor microvasculature and suppresses growth of orthotopic 231 breast carcinoma xenografts. Proceedings of the American Association for Cancer Research Annual Meeting 43: 524, 2002

Targeting vascular endothelial growth factor for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors. Cancer & Metastasis Reviews 18(4): 473-481, 1999

Isolation and characterization of neutralizing human anti-VEGF scFv antibody that specifically blocks VEGF from binding to VEGFR2. Proceedings of the American Association for Cancer Research Annual Meeting 44: 1292, 2003

Tumor Cells in Human Esophageal Adenocarcinomas Exhibit Active Vegf/Vegfr2 Signaling and, in Mice Bearing Xenografts of Transformed Barrett's Cells, Sunitinib (A Vegfr2 Inhibitor) Blocks Tumor Growth in an Angiogenesis-Independent Fashion. Gastroenterology 144(5): S-74, 2013

Sulfated polysaccharide JCS1S2 inhibits angiogenesis via targeting VEGFR2/VEGF and blocking VEGFR2/Erk/VEGF signaling. Carbohydrate Polymers 207: 502-509, 2019

A monoclonal antibody that blocks VEGF binding to VEGFR2 (KDR/Flk-1) inhibits vascular expression of Flk-1 and tumor growth in an orthotopic human breast cancer model. Angiogenesis 5(1-2): 35-44, 2003

Sulfated fucoidan FP08S2 inhibits lung cancer cell growth in vivo by disrupting angiogenesis via targeting VEGFR2/VEGF and blocking VEGFR2/Erk/VEGF signaling. Cancer Letters 382(1): 44-52, 2016

Resistance of a VEGF-producing tumor to anti-VEGF antibody: unimpeded growth of human rhabdoid tumor xenografts. Journal of Pediatric Surgery 37(3): 528-532, 2002

Development of a Fully Human Anti-Pdgfr Antibody That Suppresses Growth of Human Tumor Xenografts and Enhances Antitumor Activity of an Anti-Vegfr2 Antibody. Neoplasia 11(6): 594-604, 2009

Development of a fully human anti-PDGFRbeta antibody that suppresses growth of human tumor xenografts and enhances antitumor activity of an anti-VEGFR2 antibody. Neoplasia 11(6): 594-604, 2009

VEGF is a target molecule for peritoneal metastasis and malignant ascites in gastric cancer: prognostic significance of VEGF in ascites and efficacy of anti-VEGF monoclonal antibody. Oncotargets and Therapy 6: 1445-1451, 2013

Correlation of anti-tumor and anti-angiogenic activity of VEGFR inhibitors with inhibition of VEGFR2 phosphorylation in mice. Journal of Clinical Oncology 23(16_Suppl): 9537-9537, 2016